JINYU(SH:600201) Xin Lang Cai Jing·2026-01-11 08:25Core Logic - The company has strong R&D barriers and a rich pipeline of new products, with the non-epidemic vaccine having received clinical approval, which could become the largest growth engine in the next 3-5 years if progress is smooth [1] Industry Dynamics - The animal health sector is expected to maintain a volume increase but price decrease trend due to weak recovery in the breeding industry and profit compression, with overall gross margins declining amid intense competition and product homogenization [2] Product Development - The company is a leader in the foot-and-mouth disease vaccine market, transitioning its core product logic to the subunit non-epidemic vaccine, which has a broad market potential. The market size is expected to reach 1.75 billion yuan in the first year and 3.5 billion yuan in the second year post-launch. The subunit non-epidemic vaccine is set to enter clinical trials in July 2025, with potential revenue contributions starting from late 2027 to early 2028 [3] Marketing Strategy - The company focuses on "big products + big clients," providing comprehensive solutions and building a multi-layered marketing system. Online and overseas market expansions are showing initial success, with pet direct sales increasing over fourfold year-on-year in the first half of 2025. The company has registered sales of foot-and-mouth products in countries like Pakistan and Vietnam, with plans for deeper market penetration in Mongolia and Central Asia [4] Financial Forecast - The company expects overall revenue of 1.604 billion, 2.035 billion, and 2.521 billion yuan for 2025-2027, with year-on-year growth rates of 27.74%, 26.91%, and 23.85%. The net profit attributable to shareholders is projected to be 304 million, 398 million, and 491 million yuan, with growth rates of 178.44%, 31.04%, and 23.55%, corresponding to P/E ratios of 64, 49, and 39 times [5]